【論文摘要】The Efficacy of Deep Oscillation on Head and Neck Squamous Cell Carcinoma Cancer Patients

【論文摘要】深度層振動器對頭頸鱗狀細胞癌患者的療效

Ten-Wei He(何灯為) ； Shih-Chung Lin(林世忠)

《物理治療》 Volume 49 Issue 2 (2024/06) Pp. 138-139

https://doi.org/10.6215/FJPT.202406.P40

Abstracts

Background and Purpose: Deep Oscillation (DO) is an apparatus that is believed to produce an electrostatic field to create therapeutic vibrations within body tissues, which may improve blood and lymph flow, and help to break down fibrotic tissue. DO has been used in our hospital to treat Head and Neck Squamous Cell Carcinoma (HNSCC) patients for a long time. The aim of this study is to explore the efficacy of the DO therapy on HNSCC patients. Methods: Six patients diagnosed with HNSCC who received physical therapy after surgery, radiation or/ and chemotherapy between February 1, 2023, and November 30, 2023, were evaluated. Their physical therapy modality combinations may vary from session to session according to different recovery conditions and their responses to each modality, but DO, far-infrared ray, low power laser, and transcutaneous electrical nerve stimulation were mostly included. During these treatment sessions, these patients' responses to DO reported to therapists were examined, and the frequency of DO used during the entire study period were recorded. Results: Of 6 patients recorded, 4 reported "relaxed" during and after DO treatment, 1 reported "muscle relaxed", and 1 lost to follow up. 3 out of 6 patients continued treatment more than 3 months, and 5 patients kept DO treatment throughout the course whatever combinations of modalities changed. Conclusions: This study confirms the efficacy of DO on HNSCC patients by examining their subjective experiences during and after treatment. Furthermore, its long standing component of the treatment combination suggested that patients with HNSCC rely on DO as a long term physical therapy modality treatment. Clinical Relevance: The result of this study can be applied on physical therapy modality selection for HNSCC patients, particularly in the long-term use to relax radiogenic fibrosis tissue.